Sana Biotechnology (NASDAQ:SANA) Trading Down 3.8%

Sana Biotechnology, Inc. (NASDAQ:SANA) traded down 3.8% during trading on Thursday . The stock traded as low as $7.89 and last traded at $7.95. 182,037 shares were traded during mid-day trading, a decline of 94% from the average session volume of 3,074,527 shares. The stock had previously closed at $8.26.

Analysts Set New Price Targets

Several research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Sana Biotechnology in a research note on Friday, March 1st. JMP Securities raised their target price on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a research note on Friday, March 1st.

Sana Biotechnology Stock Down 1.6 %

The firm has a 50 day simple moving average of $8.97 and a 200 day simple moving average of $5.94.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. During the same period in the prior year, the company posted ($0.40) EPS. On average, equities analysts expect that Sana Biotechnology, Inc. will post -1.02 earnings per share for the current year.

Insider Activity

In other news, Director Robert Nelsen bought 1,818,181 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average price of $5.50 per share, for a total transaction of $9,999,995.50. Following the transaction, the director now directly owns 12,446,022 shares of the company’s stock, valued at approximately $68,453,121. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 34.90% of the company’s stock.

Institutional Trading of Sana Biotechnology

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Sana Biotechnology by 6.9% in the 4th quarter. Vanguard Group Inc. now owns 9,797,084 shares of the company’s stock worth $39,972,000 after purchasing an additional 629,499 shares during the period. State Street Corp increased its stake in Sana Biotechnology by 20.2% in the 2nd quarter. State Street Corp now owns 8,594,413 shares of the company’s stock worth $55,262,000 after purchasing an additional 1,443,483 shares during the period. BlackRock Inc. increased its stake in Sana Biotechnology by 1.1% in the 2nd quarter. BlackRock Inc. now owns 7,884,777 shares of the company’s stock worth $46,993,000 after purchasing an additional 82,950 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Sana Biotechnology by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,510,786 shares of the company’s stock worth $14,751,000 after purchasing an additional 246,294 shares during the period. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.